Schettini F, Manzionna M M, De Mattia D, Amendola F, Di Bitonto G
Minerva Pediatr. 1989 Mar;41(3):117-22.
Prevention of measles, mumps and rubella can be obtained by a single administration of a trivalent vaccine as it has already been practiced in the U.S.A. since 1970 in the Scandinavian Countries since 1982. The immunological response and the clinical reactions to a new trivalent vaccine (Triviraten-Berna) against measles, mumps, and rubella has been studied in a control group including 41 children (20 females and 21 males) aged from a minimum of 16 months to a maximum of 7 years and 4 months. All the children who resulted not to be immune to the 3 viruses by serologic tests showed a rise in the antibody titer with 100% seroconversion, whereas in those resulting to be already immune to one of the 3 viruses, a persistent antibody titer or an increase was revealed. Neither general nor local clinical reactions were observed. These results suggest that this trivalent vaccine is highly effective, without negative effects and helpful for a mass prevention of such viral diseases.
自1970年起在美国以及自1982年起在斯堪的纳维亚国家，通过单次接种三价疫苗即可预防麻疹、腮腺炎和风疹。针对一种预防麻疹、腮腺炎和风疹的新型三价疫苗（Triviraten-Berna）的免疫反应和临床反应，在一个对照组中进行了研究，该对照组包括41名儿童（20名女性和21名男性），年龄最小为16个月，最大为7岁4个月。所有经血清学检测对这三种病毒均无免疫力的儿童，抗体滴度均有所上升，血清转化率达100%，而那些对这三种病毒中的一种已有免疫力的儿童，则显示出抗体滴度持续存在或有所增加。未观察到全身或局部临床反应。这些结果表明，这种三价疫苗非常有效，没有负面影响，有助于大规模预防此类病毒性疾病。
